Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Beneficial effects of Ginkgo biloba leaf extract on inflammatory markers: A systematic review and meta-analysis of the clinical trials.

  • 2022-07-03
  • Phytotherapy research : PTR 36(9)
    • Seyedeh Neda Mousavi
    • Mahboobe Hosseinikia
    • Esmaeil Yousefi Rad
    • Somayeh Saboori

Study Design

Type
Meta-Analysis
Sample size
n = 104
Population
1,104 participants
Methods
Systematic search on four databases (PubMed, Scopus, Web of Science, Google Scholar) up to October 2021; 17 trials included
Duration
1-24 weeks
The beneficial effects of Ginkgo biloba on cardio-metabolic markers have been reported. However, its effect on inflammation is not assessed in any meta-analysis. We performed a systematic review of randomized controlled trials evaluating the effects of Ginkgo biloba leaf extract (GBLE) on serum C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels. A systematic search was performed on four databases, including PubMed, Scopus, Web of Science, and Google Scholar, up to October 2021. After screening, 17 trials met our inclusion criteria. Trials were of 1-24 weeks of duration and included 1,104 participants. In the meta-analysis, the weighted mean differences (WMD) in change for serum CRP were -1.5 mg/L (95% CI: -2.16, -0.85, p < 0.001). Moreover, WMD for serum IL-6 and TNF-α were in favor of the GBLE compared to the placebo [(-16.86 pg/mL, 95% CI: -19.38, -14.34, p < 0.001); and (-4.19 pg/mL, 95%CI: -5.14, -3.23, p < 0.001), respectively]. Subgroup analysis showed that GBLE has a beneficial effect on serum CRP at the baseline levels≥3 mg/L and doses<500 mg/day. This meta-analysis showed that the GBLE could reduce serum inflammatory markers. Therefore, this medicinal herb might be a possible strategy for inflammation control.

Research Insights

  • Ginkgo→Reduced C-Reactive Protein Levels

    Subgroup analysis showed that GBLE has a beneficial effect on serum CRP at the baseline levels≥3 mg/L and doses<500 mg/day

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    doses <500 mg/day
  • Ginkgo→Reduced Interleukin-6 Levels

    WMD for serum IL-6 and TNF-α were in favor of the GBLE compared to the placebo [(-16.86 pg/mL, 95% CI: -19.38, -14.34, p < 0.001)]

    Effect
    Beneficial
    Effect size
    Large
    Dose
    not specified in abstract for IL-6
  • Ginkgo→Reduced Tumor Necrosis Factor Alpha

    WMD for serum IL-6 and TNF-α were in favor of the GBLE compared to the placebo [(-4.19 pg/mL, 95%CI: -5.14, -3.23, p < 0.001)]

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    not specified in abstract for TNF-α
Back to top